Эрадикация Helicobacter pylori и абсорбция препаратов Л-ДОПА. Абстракт.

[Mikhail]

NEUROLOGY 2006;66:1824-1829
© 2006 American Academy of Neurology
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations
M. Pierantozzi, PhD, A. Pietroiusti, MD, L. Brusa, MD, S. Galati, MD, A. Stefani, MD, G. Lunardi, PhD, E. Fedele, PhD, G. Sancesario, MD, G. Bernardi, MD, A. Bergamaschi, MD, A. Magrini, MD, P. Stanzione, MD and A. Galante, MD

From the IRCCS Santa Lucia Foundation (M.P., L.B., S.G., A.S., G.S., G.B., P.S.) and Departments of Neuroscience (M.P., L.B., S.G., A.S., G.S., G.B., P.S.), Internal Medicine (A.P., A.G.), and Occupational Medicine (A.B., A.M.), "Tor Vergata" University, and S. Raffaele Hospital (A.P., A.G.), Rome, and Departments of Oncology, Biology, Genetics, Pharmacology, and Neuroscience (G.L.) and Experimental Medicine (E.F.), Pharmacology and Toxicology Division, Genoa University, Italy.

Address correspondence and reprint requests to Dr. A. Pietroiusti, Department of Internal Medicine, "Tor Vergata" University, Viale Montpellier 1, 00133, Rome, Italy; e-mail: pietroiusti{at}med.uniroma2.it

Objective: To investigate if Helicobacter pylori (HP) eradication could make an effective and long-lasting improvement in the pharmacokinetic and clinical response to l-dopa in patients with Parkinson disease (PD) and motor fluctuations.

Methods: In a group of 34 HP-infected, motor-fluctuating patients with PD, the short-term (1-week) and long-term (3-month) beneficial effect of HP eradication (n = 17) was investigated in a double-blind fashion in comparison with a generic antioxidant treatment (n = 17), by means of pharmacokinetic, clinical, and gastrointestinal assessments. Results were compared with placebo treatment.

Results: Differently from the antioxidant-treated patients, the HP-eradicated patients showed a significant increase of l-dopa absorption, which was coupled with a significant improvement of clinical disability and with a prolonged "on-time" duration, whereas gastritis/duodenitis scores significantly decreased in line with a better l-dopa pharmacokinetics.

Conclusions: These data demonstrate a reversible Helicobacter pylori (HP)–induced interference with l-dopa clinical response related to the impaired drug absorption, probably due to active gastroduodenitis. Therefore, the authors suggest that HP eradication may improve the clinical status of infected patients with Parkinson disease and motor fluctuations by modifying l-dopa pharmacokinetics.

[OrFun]

These data demonstrate a reversible Helicobacter pylori (HP)–induced interference with l-dopa clinical response related to the impaired drug absorption, probably due to active gastroduodenitis. (с) . Действительно, видимо абсорбция связана с активностью гастодуоденита (интересно , ее морфологически исследовали ?).Михаил , извиняюсь , а генерализованая антиоксидантная терапия это ингибиторы МАО-В, типа юмакса или когнитива ?